OTR-004

OTR-004 is a discovery-stage therapeutic candidate being developed by OTR Therapeutics for the treatment of unspecified oncology indications. The drug is based on the company's proprietary ReGeneraTing Agent (RGTA) technology, which utilizes synthetic heparan sulfate mimics to restore and stabilize the extracellular matrix (ECM) microenvironment. RGTAs are chemically substituted dextran polymers (specifically carboxymethyl benzylamide sulfonate dextrans) designed to replace degraded heparan sulfates in the ECM. By binding to and protecting endogenous heparin-binding growth factors and cytokines from proteolytic degradation, OTR-004 aims to modulate the tumor microenvironment and potentially inhibit cancer progression. As of the latest sponsor updates, the specific molecular targets and precise mechanism of action for OTR-004 in oncology remain undisclosed.